Overview of long-acting Beta2-agonists (LABA) plus corticosteroids versus LABA alone for chronic obstructive pulmonary disease
Brady B, Siebert U, Sroczynski G, Murphy G, Husereau D, Sherman M, Wong W, Mensinkai S
Record ID 32007000132
English
Authors' objectives:
The objectives were; : To determine the cost-effectiveness of CT versus LABA alone as a first-line agent in the treatment of COPD in Canada. : To measure the global economic impact of introducing CT versus LABA in Canada.
Authors' recommendations:
Implications for Decision Making
CT in all COPD stages is more effective than LABA alone. Available evidence suggests that CT results in fewer overall exacerbations and improved quality of life measures, compared with treatment by LABA alone. There is no evidence to suggest that mortality differs with different strategies.
Different treatment strategies will vary in cost-effectiveness. The lifetime cost of using a LABA (discounted at 5%) is 9,636 Canadian dollars per COPD patient. Adding an ICS for the most severe patients (strategy 2) results in an increase of 93 Canadian dollars per patient; strategy 3 increases costs by an additional 321 Canadian dollars; and strategy 4 increases costs by 3,120 Canadian dollars. Each strategy is associated with an additional increase of 0.01 quality-adjusted life year (QALY) per patient. Strategies 2 and 3 may be perceived as cost-effective by those who are prepared to pay up to 50,000 Canadian dollars for a QALY.
CT requires additional resources. Switching all patients who are >65 years old and only receive a LABA without an ICS to CT treatment would require, by extrapolation, an additional 3.3 million Canadian dollars in Alberta, and 43.7 million Canadian dollars nationally.
Authors' methods:
Overview, Cost study
Details
Project Status:
Completed
Year Published:
2007
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Adrenal Cortex Hormones
- Adrenergic beta-Agonists
- Pulmonary Disease, Chronic Obstructive
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.